EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel
It is intended for the treatment of adult patiens with relapsed and refractory multiple myeloma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described
Genomic and histologic analyses of the KRYSTAL-1 study
ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in High-Risk Neuroblastoma
SIOPEN data contribute to the rationale for future clinical trials introducing ALK targeted treatment in the frontline setting
Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC Subtypes
The results of phase II study in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small cell lung cancers harbouring MET exon 14 skipping alterations
ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
The results form a prospective multicentre study provide a rationale for designing ctDNA-based risk-adaptive CAR T-cell clinical studies
Signal of Increased Risk of Major Cardiovascular Events and Cancer with Tofacitinib
EMA’s Pharmacovigilance Risk Assessment Committee concluded review of a safety signal
Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy
The results of the ECOG-ACRIN EA1131 study in basal subtype triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Avapritinib, a kinase inhibitor, was evaluated in the EXPLORER and PATHFINDER studies
Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to EGFR TKI Therapy
Targeting unmet need in EGFR tyrosine kinase inhibitor resistant non-small cell lung cancer
High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
Pivotal results of the phase II, ZUMA-3 study
Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma
Data support metronomic capecitabine as a potential adjuvant therapy for nasopharyngeal carcinoma
Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab
A novel checkpoint inhibitors combination of nivolumab plus relatlimab validate dual LAG-3 and PD-1 inhibition